insights_auto
Why is KYNB up 2,85%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
6,13 $
arrow_upward
+2,85%(+0,17) 1D
7 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
5,85 $
High
6,35 $
Low
5,85 $
Mkt. cap
24,82 млн
Avg. vol.
26,52 мың
Volume
16,83 мың
P/E ratio
0,14
52-wk high
9,70 $
52-wk low
5,62 $
EPS
45,30 $
Beta
1,05
Shares outstanding
4,05 млн
No. of employees
34
Open
5,85 $
High
6,35 $
Low
5,85 $
Mkt. cap
24,82 млн
Avg. vol.
26,52 мың
Volume
16,83 мың
P/E ratio
0,14
52-wk high
9,70 $
52-wk low
5,62 $
EPS
45,30 $
Beta
1,05
Shares outstanding
4,05 млн
No. of employees
34
News stories
From web sources and news partners
Investing.com Canada
·
1 күн бұрын
Form 4 Kyntra Bio Inc For: 6 October By Investing.com
Stock Titan
·
1 күн бұрын
A director receives 14,000 Kyntra Bio (KYNB) stock options with a $6.50 exercise price.
TipRanks
·
1 күн бұрын
Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision
AD HOC NEWS
·
2 күн бұрын
Kyntra Bio stock falls 3.02 percent as board changes
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
Founded1993 ж. 01 қаң.
HeadquartersСан Франсиско, Калифорния, Америка Құрама Штаттары
Sector-
Websitekyntrabio.com